Smith MR - Search Results

1

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.

Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Isbarn H, et al. Among authors: smith mr. Eur Urol. 2009 Jan;55(1):62-75. doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14. Eur Urol. 2009. PMID: 18945543 Free PMC article. Review.

2

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.

Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C; Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Carroll PR, et al. Among authors: smith mr. Urology. 2002 Sep;60(3 Suppl 1):1-6. doi: 10.1016/s0090-4295(02)01559-5. Urology. 2002. PMID: 12231036 Review. No abstract available.

3

Osteoporosis during androgen deprivation therapy for prostate cancer.

Smith MR. Smith MR. Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. Urology. 2002. PMID: 12231056 Review.

4

Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.

Smith MR. Smith MR. Cancer Metastasis Rev. 2002;21(2):159-66. doi: 10.1023/a:1020840311573. Cancer Metastasis Rev. 2002. PMID: 12465755 Review.

5

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

Smith MR, Fallon MA, Goode MJ. Smith MR, et al. Urology. 2003 Jan;61(1):127-31. doi: 10.1016/s0090-4295(02)02006-x. Urology. 2003. PMID: 12559282

6

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Smith MR, et al. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95. J Urol. 2003. PMID: 12771706 Clinical Trial.

7

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Oh WK, et al. Among authors: smith mr. Urology. 2003 Jul;62(1):99-104. doi: 10.1016/s0090-4295(03)00145-6. Urology. 2003. PMID: 12837431 Clinical Trial.

8

Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.

Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Carroll PR, et al. Among authors: smith mr. J Urol. 2003 Dec;170(6 Pt 2):S3-5. doi: 10.1097/01.ju.0000095101.18470.a0. J Urol. 2003. PMID: 14610403 Review. No abstract available.

9

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.

Smith MR. Smith MR. Urology. 2004 Apr;63(4):742-5. doi: 10.1016/j.urology.2003.10.063. Urology. 2004. PMID: 15072892 Clinical Trial.

10

Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.

Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Carroll PR, et al. Among authors: smith mr. J Urol. 2004 Nov;172(5 Pt 2):S3-5. doi: 10.1097/01.ju.0000142276.19511.ac. J Urol. 2004. PMID: 15535434 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,175 results

Search Page

Filters